Abstract
We outline and evaluate competing explanations of three relationships that have consistently been found between cannabis use and the use of other illicit drugs, namely, (1) that cannabis use typically precedes the use of other illicit drugs; and that (2) the earlier cannabis is used, and (3) the more regularly it is used, the more likely a young person is to use other illicit drugs. We consider three major competing explanations of these patterns: (1) that the relationship is due to the fact that there is a shared illicit market for cannabis and other drugs which makes it more likely that other illicit drugs will be used if cannabis is used; (2) that they are explained by the characteristics of those who use cannabis; and (3) that they reflect a causal relationship in which the pharmacological effects of cannabis on brain function increase the likelihood of using other illicit drugs. These explanations are evaluated in the light of evidence from longitudinal epidemiological studies, simulation studies, discordant twin studies and animal studies. The available evidence indicates that the association reflects in part but is not wholly explained by: (1) the selective recruitment to heavy cannabis use of persons with pre-existing traits (that may be in part genetic) that predispose to the use of a variety of different drugs; (2) the affiliation of cannabis users with drug using peers in settings that provide more opportunities to use other illicit drugs at an earlier age; (3) supported by socialisation into an illicit drug subculture with favourable attitudes towards the use of other illicit drugs. Animal studies have raised the possibility that regular cannabis use may have pharmacological effects on brain function that increase the likelihood of using other drugs. We conclude with suggestions for the type of research studies that will enable a decision to be made about the relative contributions that social context, individual characteristics, and drug effects make to the relationship between cannabis use and the use of other drugs.
Wayne D. Hall PhD, Office of Public Policy and Ethics, Institute for Molecular Bioscience, University of Queensland, St Lucia, Qld 4072. Phone: + 61 7 3346-2150. Fax: + 61 7 3346-2159. Email: [email protected]. Michael Lynskey PhD, Department of Psychiatry, University of Washington School of Medicine, St Louis, Missouri, USA.
Wayne D. Hall PhD, Office of Public Policy and Ethics, Institute for Molecular Bioscience, University of Queensland, St Lucia, Qld 4072. Phone: + 61 7 3346-2150. Fax: + 61 7 3346-2159. Email: [email protected]. Michael Lynskey PhD, Department of Psychiatry, University of Washington School of Medicine, St Louis, Missouri, USA.